
[ Wed, Aug 05th 2009 ] - Market Wire
[ Wed, Aug 05th 2009 ] - Market Wire
[ Wed, Aug 05th 2009 ] - Market Wire
[ Wed, Aug 05th 2009 ] - Market Wire
[ Wed, Aug 05th 2009 ] - Market Wire

[ Tue, Aug 04th 2009 ] - Market Wire
[ Tue, Aug 04th 2009 ] - Market Wire
[ Tue, Aug 04th 2009 ] - Market Wire
[ Tue, Aug 04th 2009 ] - Market Wire
[ Tue, Aug 04th 2009 ] - Market Wire

[ Mon, Aug 03rd 2009 ] - Market Wire
[ Mon, Aug 03rd 2009 ] - Market Wire
[ Mon, Aug 03rd 2009 ] - Market Wire
[ Mon, Aug 03rd 2009 ] - Market Wire
[ Mon, Aug 03rd 2009 ] - Market Wire

[ Sat, Aug 01st 2009 ] - Market Wire

[ Fri, Jul 31st 2009 ] - Market Wire
[ Fri, Jul 31st 2009 ] - Market Wire
[ Fri, Jul 31st 2009 ] - Market Wire
[ Fri, Jul 31st 2009 ] - Market Wire
[ Fri, Jul 31st 2009 ] - Market Wire

[ Thu, Jul 30th 2009 ] - Market Wire
[ Thu, Jul 30th 2009 ] - Market Wire
[ Thu, Jul 30th 2009 ] - Market Wire
[ Thu, Jul 30th 2009 ] - Market Wire
[ Thu, Jul 30th 2009 ] - Market Wire

[ Wed, Jul 29th 2009 ] - Market Wire
[ Wed, Jul 29th 2009 ] - Market Wire
[ Wed, Jul 29th 2009 ] - Market Wire
[ Wed, Jul 29th 2009 ] - Market Wire
[ Wed, Jul 29th 2009 ] - Market Wire

[ Tue, Jul 28th 2009 ] - Market Wire
[ Tue, Jul 28th 2009 ] - Market Wire
[ Tue, Jul 28th 2009 ] - Market Wire
[ Tue, Jul 28th 2009 ] - Market Wire
[ Tue, Jul 28th 2009 ] - Market Wire

[ Mon, Jul 27th 2009 ] - Market Wire
[ Mon, Jul 27th 2009 ] - Market Wire
[ Mon, Jul 27th 2009 ] - Market Wire
[ Mon, Jul 27th 2009 ] - Market Wire
[ Mon, Jul 27th 2009 ] - Market Wire

[ Sat, Jul 25th 2009 ] - Market Wire

[ Fri, Jul 24th 2009 ] - Market Wire
[ Fri, Jul 24th 2009 ] - Market Wire

[ Thu, Jul 23rd 2009 ] - Market Wire
[ Thu, Jul 23rd 2009 ] - Market Wire
[ Thu, Jul 23rd 2009 ] - Market Wire
[ Thu, Jul 23rd 2009 ] - Market Wire
[ Thu, Jul 23rd 2009 ] - Market Wire

[ Wed, Jul 22nd 2009 ] - Market Wire
[ Wed, Jul 22nd 2009 ] - Market Wire
[ Wed, Jul 22nd 2009 ] - Market Wire
[ Wed, Jul 22nd 2009 ] - Market Wire
[ Wed, Jul 22nd 2009 ] - Market Wire

[ Tue, Jul 21st 2009 ] - Market Wire
[ Tue, Jul 21st 2009 ] - Market Wire
[ Tue, Jul 21st 2009 ] - Market Wire
[ Tue, Jul 21st 2009 ] - Market Wire
[ Tue, Jul 21st 2009 ] - Market Wire

[ Mon, Jul 20th 2009 ] - Market Wire
[ Mon, Jul 20th 2009 ] - Market Wire
[ Mon, Jul 20th 2009 ] - Market Wire
[ Mon, Jul 20th 2009 ] - Market Wire
[ Mon, Jul 20th 2009 ] - Market Wire

[ Sun, Jul 19th 2009 ] - Market Wire

[ Fri, Jul 17th 2009 ] - Market Wire
[ Fri, Jul 17th 2009 ] - Market Wire
[ Fri, Jul 17th 2009 ] - Market Wire
[ Fri, Jul 17th 2009 ] - Market Wire

[ Thu, Jul 16th 2009 ] - Market Wire
[ Thu, Jul 16th 2009 ] - Market Wire
[ Thu, Jul 16th 2009 ] - Market Wire
[ Thu, Jul 16th 2009 ] - Market Wire

[ Wed, Jul 15th 2009 ] - Market Wire
[ Wed, Jul 15th 2009 ] - Market Wire
[ Wed, Jul 15th 2009 ] - Market Wire
[ Wed, Jul 15th 2009 ] - Market Wire

[ Tue, Jul 14th 2009 ] - Market Wire
[ Tue, Jul 14th 2009 ] - Market Wire
[ Tue, Jul 14th 2009 ] - Market Wire
[ Tue, Jul 14th 2009 ] - Market Wire

[ Mon, Jul 13th 2009 ] - Market Wire
[ Mon, Jul 13th 2009 ] - Market Wire
[ Mon, Jul 13th 2009 ] - Market Wire
[ Mon, Jul 13th 2009 ] - Market Wire

[ Fri, Jul 10th 2009 ] - Market Wire
[ Fri, Jul 10th 2009 ] - Market Wire

[ Thu, Jul 09th 2009 ] - Market Wire
[ Thu, Jul 09th 2009 ] - Market Wire
[ Thu, Jul 09th 2009 ] - Market Wire
[ Thu, Jul 09th 2009 ] - Market Wire

[ Wed, Jul 08th 2009 ] - Market Wire
[ Wed, Jul 08th 2009 ] - Market Wire
[ Wed, Jul 08th 2009 ] - Market Wire
[ Wed, Jul 08th 2009 ] - Market Wire

[ Tue, Jul 07th 2009 ] - Market Wire
[ Tue, Jul 07th 2009 ] - Market Wire
[ Tue, Jul 07th 2009 ] - Market Wire
[ Tue, Jul 07th 2009 ] - Market Wire

[ Mon, Jul 06th 2009 ] - Market Wire
[ Mon, Jul 06th 2009 ] - Market Wire
[ Mon, Jul 06th 2009 ] - Market Wire
[ Mon, Jul 06th 2009 ] - Market Wire

[ Fri, Jul 03rd 2009 ] - Market Wire
[ Fri, Jul 03rd 2009 ] - Market Wire

[ Thu, Jul 02nd 2009 ] - Market Wire
[ Thu, Jul 02nd 2009 ] - Market Wire
[ Thu, Jul 02nd 2009 ] - Market Wire
[ Thu, Jul 02nd 2009 ] - Market Wire

[ Wed, Jul 01st 2009 ] - Market Wire
[ Wed, Jul 01st 2009 ] - Market Wire
[ Wed, Jul 01st 2009 ] - Market Wire

[ Tue, Jun 30th 2009 ] - Market Wire
[ Tue, Jun 30th 2009 ] - Market Wire
[ Tue, Jun 30th 2009 ] - Market Wire
[ Tue, Jun 30th 2009 ] - Market Wire

[ Mon, Jun 29th 2009 ] - Market Wire
[ Mon, Jun 29th 2009 ] - Market Wire
[ Mon, Jun 29th 2009 ] - Market Wire
[ Mon, Jun 29th 2009 ] - Market Wire

[ Fri, Jun 26th 2009 ] - Market Wire
[ Fri, Jun 26th 2009 ] - Market Wire
[ Fri, Jun 26th 2009 ] - Market Wire

[ Thu, Jun 25th 2009 ] - Market Wire
[ Thu, Jun 25th 2009 ] - Market Wire
[ Thu, Jun 25th 2009 ] - Market Wire
[ Thu, Jun 25th 2009 ] - Market Wire

[ Wed, Jun 24th 2009 ] - Market Wire
[ Wed, Jun 24th 2009 ] - Market Wire
[ Wed, Jun 24th 2009 ] - Market Wire

[ Tue, Jun 23rd 2009 ] - Market Wire
[ Tue, Jun 23rd 2009 ] - Market Wire
[ Tue, Jun 23rd 2009 ] - Market Wire
[ Tue, Jun 23rd 2009 ] - Market Wire

[ Mon, Jun 22nd 2009 ] - Market Wire
[ Mon, Jun 22nd 2009 ] - Market Wire
[ Mon, Jun 22nd 2009 ] - Market Wire
[ Mon, Jun 22nd 2009 ] - Market Wire

[ Sun, Jun 21st 2009 ] - Market Wire

[ Fri, Jun 19th 2009 ] - Market Wire
[ Fri, Jun 19th 2009 ] - Market Wire
[ Fri, Jun 19th 2009 ] - Market Wire
[ Fri, Jun 19th 2009 ] - Market Wire

[ Thu, Jun 18th 2009 ] - Market Wire
[ Thu, Jun 18th 2009 ] - Market Wire
[ Thu, Jun 18th 2009 ] - Market Wire
[ Thu, Jun 18th 2009 ] - Market Wire

[ Wed, Jun 17th 2009 ] - Market Wire
[ Wed, Jun 17th 2009 ] - Market Wire
[ Wed, Jun 17th 2009 ] - Market Wire
[ Wed, Jun 17th 2009 ] - Market Wire

[ Tue, Jun 16th 2009 ] - Market Wire
[ Tue, Jun 16th 2009 ] - Market Wire
[ Tue, Jun 16th 2009 ] - Market Wire
[ Tue, Jun 16th 2009 ] - Market Wire

[ Mon, Jun 15th 2009 ] - Market Wire
[ Mon, Jun 15th 2009 ] - Market Wire
[ Mon, Jun 15th 2009 ] - Market Wire
[ Mon, Jun 15th 2009 ] - Market Wire

[ Fri, Jun 12th 2009 ] - Market Wire
[ Fri, Jun 12th 2009 ] - Market Wire
[ Fri, Jun 12th 2009 ] - Market Wire

[ Thu, Jun 11th 2009 ] - Market Wire
[ Thu, Jun 11th 2009 ] - Market Wire
[ Thu, Jun 11th 2009 ] - Market Wire
[ Thu, Jun 11th 2009 ] - Market Wire

[ Wed, Jun 10th 2009 ] - Market Wire
[ Wed, Jun 10th 2009 ] - Market Wire
[ Wed, Jun 10th 2009 ] - Market Wire
[ Wed, Jun 10th 2009 ] - Market Wire

[ Tue, Jun 09th 2009 ] - Market Wire
[ Tue, Jun 09th 2009 ] - Market Wire
[ Tue, Jun 09th 2009 ] - Market Wire
[ Tue, Jun 09th 2009 ] - Market Wire

[ Mon, Jun 08th 2009 ] - Market Wire
[ Mon, Jun 08th 2009 ] - Market Wire
[ Mon, Jun 08th 2009 ] - Market Wire
[ Mon, Jun 08th 2009 ] - Market Wire

[ Sun, Jun 07th 2009 ] - Market Wire

[ Fri, Jun 05th 2009 ] - Market Wire
[ Fri, Jun 05th 2009 ] - Market Wire
[ Fri, Jun 05th 2009 ] - Diet Pill Analyst
[ Fri, Jun 05th 2009 ] - Market Wire
[ Fri, Jun 05th 2009 ] - Market Wire

[ Thu, Jun 04th 2009 ] - Market Wire
[ Thu, Jun 04th 2009 ] - Market Wire
[ Thu, Jun 04th 2009 ] - Market Wire
[ Thu, Jun 04th 2009 ] - Market Wire

[ Wed, Jun 03rd 2009 ] - Market Wire
[ Wed, Jun 03rd 2009 ] - Market Wire
[ Wed, Jun 03rd 2009 ] - Market Wire
[ Wed, Jun 03rd 2009 ] - Market Wire

[ Tue, Jun 02nd 2009 ] - Market Wire
[ Tue, Jun 02nd 2009 ] - Market Wire
[ Tue, Jun 02nd 2009 ] - Market Wire
[ Tue, Jun 02nd 2009 ] - Market Wire

[ Mon, Jun 01st 2009 ] - Market Wire
[ Mon, Jun 01st 2009 ] - Market Wire
[ Mon, Jun 01st 2009 ] - Market Wire
ConjuChem raises $5 million in non-dilutive financing
//health-fitness.news-articles.net/content/2009/ .. -raises-5-million-in-non-dilutive-financing.html
Published in Health and Fitness on Wednesday, July 8th 2009 at 15:11 GMT, Last Modified on 2009-07-08 15:11:10 by Market Wire
Published in Health and Fitness on Wednesday, July 8th 2009 at 15:11 GMT, Last Modified on 2009-07-08 15:11:10 by Market Wire

MONTREAL, July 8 /CNW/ - ConjuChem Biotechnologies Inc (TSX:CJB) today announced that it has entered into an agreement with Colabor Income Fund (TSX:CLB.UN), a Québec-based income trust, that will provide gross proceeds of approximately $5 million in non-dilutive capital to ConjuChem concurrent with a reorganization of the Company. "This non-dilutive transaction, accomplished in a challenging economic environment, strengthens our balance sheet and provides us with greater flexibility as we pursue a partnership for our lead diabetes drug, PC-DAC(TM):Exendin-4," said Mark Perrin, President and CEO. "We recently reported results from the Phase II program for PC-DAC(TM):Exendin-4 at the American Diabetes Association's 69th Annual Scientific Sessions demonstrating that our long-lasting GLP-1 agonist achieved statistically significant reductions in HbA1c and weight and was extremely well tolerated." The non-dilutive transaction involves a corporate reorganization to be completed under a court supervised Plan of Arrangement. ConjuChem will transfer its assets and liabilities, including the proceeds from this transaction, to a newly incorporated subsidiary company, 4523482 Canada Inc. ("New ConjuChem OpCo"). On completion of the transaction, ConjuChem securityholders will have exchanged their ConjuChem securities on a one-for-one basis for securities of a parent company of New ConjuChem OpCo which shall subsequently amalgamate with New ConjuChem OpCo ("New ConjuChem"). New ConjuChem will carry on ConjuChem's business operations as a public entity and will retain all rights to related intellectual property as before the transaction. As part of the Plan of Arrangement, Colabor unitholders, on completion of the transaction, will own 100% of the shares of the original ConjuChem entity. Completion of the transaction is subject to receipt of court and other regulatory approvals and consents. It must also be approved (i) by at least 66 2/3 percent of votes cast by ConjuChem shareholders, (ii) at least 66 2/3 percent of votes cast by ConjuChem optionholders, warrantholders and debentureholders, and (iii) by at least 66 2/3 percent of votes cast by Colabor unitholders. Based on a number of factors, including a fairness opinion rendered by ConjuChem's financial advisor for the transaction, ConjuChem's Board of Directors unanimously recommends that ConjuChem securityholders approve the transaction. Additional details regarding the transaction will be provided to ConjuChem securityholders in an information circular to be mailed in mid-July. The information circular will also be available at [ www.conjuchem.com ] and[ www.sedar.com ]. A special meeting of securityholders will be held in August 2009 at the offices of McCarthy Tétrault LLP, Suite 2500, 1000, De La Gauchetière Street West, Montréal, Québec. The transaction is expected to close in August 2009 subject to the satisfaction of customary closing conditions. About ConjuChem Biotechnologies Inc. ConjuChem, a developer of next generation medicines from therapeutic peptides, creates long-acting compounds based on its proprietary bioconjugation platform technology. ConjuChem has two major development programs: PC-DAC(TM):Exendin-4, a GLP-1 receptor agonist in Phase II clinical development and PC-Insulin, a long-acting basal insulin in preclinical development. Detailed descriptions of ConjuChem and its technologies can be viewed on ConjuChem's website [ www.conjuchem.com ]. Forward-Looking Statements This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect ConjuChem's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, the obtaining of court and other regulatory approvals and consents, the satisfaction of closing conditions, adjustment provisions relating to the proceeds of the transaction, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in ConjuChem's ongoing filings with the Canadian securities regulatory authorities which filings can be found at [ www.sedar.com ]. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. ConjuChem undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.
For further information: Mark Perrin, President and CEO, ConjuChem Biotechnologies Inc., (514) 844-5558 ext. 311, [ perrin@conjuchem.com ]; James Smith, Investor Relations, (416) 815-0700 ext. 229, [ JSmith@equicomgroup.com ]
Publication Contributing Sources
Similar Health and Fitness Publications
[ Thu, Jun 11th 2009 ] - Market Wire
[ Mon, Jun 08th 2009 ] - Market Wire
[ Fri, Jun 05th 2009 ] - Market Wire
[ Wed, May 27th 2009 ] - Market Wire
[ Wed, May 20th 2009 ] - Market Wire
[ Tue, May 19th 2009 ] - Market Wire
[ Tue, May 19th 2009 ] - Market Wire
[ Wed, May 13th 2009 ] - Market Wire
[ Wed, May 13th 2009 ] - Market Wire
[ Mon, May 11th 2009 ] - Market Wire
[ Thu, Feb 26th 2009 ] - Market Wire